Marie Skłodowska-Curie Action
Innovative Training Networks (ITN)

2015-2019

 

Funded by

marie curie actions   Marie Curie Actions

 

 

unnamed   
EU Horizon 2020

 

 

european union logo   European Union

 

University of Glassgow

glasgow

 

Webpage: http://www.gla.ac.uk/researchinstitutes/biology and http://www.gla.ac.uk/researchinstitutes/iii/

 

General description
The Molecular Pharmacology Group at the University of Glasgow is led by Graeme Milligan and has been identified as one of the leading GPCR teams in the world (see www.gproteins.com/labs.php). The team focuses on the pharmacology, structure and regulation of GPCRs and their interacting proteins and how the behaviour of GPCRs can be adapted to develop novel platforms for early stage drug discovery. The Molecular Pharmacology Group has published nearly 500 papers and their studies have been cited more than 20,000 times.

The Chemokine Research Group (CRG) at the University of Glasgow is led by Gerry Graham and represents one of the largest collections of chemokine researchers in Europe (www.chemokineresearchgroup.org). CRG has over 25 years of experience of working with chemokines and their receptors during which time it has made fundamental contributions to this important field. Most recently CRG researchers have been at the forefront of atypical chemokine receptor biology.

 

Key research facilities, infrastructures and equipment
UGL is the lead academic partner for an ‘Innovation centre’ based in Glasgow that will focus on the development of personalised medicine through the use of next generation genomic sequencing and analyses. A major aim is to develop personalised approaches to treatment and also decrease attrition rates and potential withdrawal of medicines. The Molecular Pharmacology Group and CRG are underpinned by state of the art facilities including the Glasgow Polyomics Facility that provides a full array of genomic, transcriptomic, proteomic and metabolomic analyses. High-end imaging capabilities allow millisecond kinetic analysis of ligand binding and debinding from GPCRs. Physiological outcomes of GPCR activation and its relevance to cancer are integrated into the work via direct links with the Institute of Cancer Sciences at UGL including the use of a broad range of mouse models of disease. Collaborations with a wide range of companies within the pharmaceutical industry have previously resulted in a series of successful outcomes. The group has also trained many early career researchers who have subsequently moved to work for European SMEs. CRG is well equipped for the proposed study and also benefits from access to all the facilities mentioned above.

Lijndik